Circulating tumor cells in prostate cancer: beyond enumeration

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Circulating tumor cells (CTCs) are rare cancer cells in the bloodstream.
• CTC enumeration is an established prognostic biomarker in prostate cancer.
• Emerging research highlights the significance of CTC characteristics beyond mere counts.

Purpose of the Study:

• To explore the evolving role of CTCs in prostate cancer diagnostics and prognostics.
• To discuss how technological advancements enable deeper analysis of CTCs.
• To highlight new applications of CTCs in managing prostate cancer.

Main Methods:

• Liquid biopsy techniques.
• Examination of CTC morphology, function, and molecular content.
• Analysis of tumor evolution and therapy resistance mechanisms using CTCs.

Main Results:

• CTCs provide critical prognostic information in prostate cancer.
• Technological progress allows for detailed CTC analysis.
• New CTC applications are emerging for patient treatment.

Conclusions:

• Advanced CTC analysis offers significant insights beyond simple enumeration.
• These insights are crucial for understanding tumor evolution and resistance.
• Recent breakthroughs in CTC technology promise to transform prostate cancer care.